NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) issued its earnings results on Wednesday, February, 6th. The biotechnology company reported $1.25 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.46 by $0.21. The biotechnology company had revenue of $69.89 million for the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. Enanta Pharmaceuticals's revenue was up 83.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.59 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

6 equities research analysts have issued 12 month price targets for Enanta Pharmaceuticals' stock. Their predictions range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $102.60 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

News coverage about ENTA stock has trended somewhat positive on Saturday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.

Some companies that are related to Enanta Pharmaceuticals include SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Nektar Therapeutics (NKTR), Amarin (AMRN), Alkermes (ALKS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY) and FibroGen (FGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), NVIDIA (NVDA), Zoetis (ZTS), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Gilead Sciences (GILD), Dollar Tree (DLTR), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG) and Mastercard (MA).

Enanta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.24%), First Manhattan Co. (3.50%), Dimensional Fund Advisors LP (3.21%), Krensavage Asset Management LLC (2.76%), Krensavage Asset Management LLC (2.75%) and Acadian Asset Management LLC (1.79%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Acadian Asset Management LLC, FMR LLC, Great Point Partners LLC, Mackenzie Financial Corp, First Trust Advisors LP, First Manhattan Co. and Barclays PLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Citigroup Inc., Candriam Luxembourg S.C.A., Two Sigma Investments LP, Krensavage Asset Management LLC, Krensavage Asset Management LLC, Millennium Management LLC and KBC Group NV. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $95.41.

Enanta Pharmaceuticals has a market capitalization of $1.85 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is http://www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]